Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Piper ...

Biogen (NASDAQ:BIIB – Free Report) had its price target trimmed by HC Wainwright from $300.00 to $241.00 in a report issued ...

Biogen (NASDAQ:BIIB – Free Report) had its target price lowered by Truist Financial from $220.00 to $210.00 in a research ...

Biogen (NASDAQ:BIIB – Free Report) had its price target decreased by BMO Capital Markets from $156.00 to $139.00 in a report ...

Savant Capital LLC raised its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 11.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 4,179 shares of the biotechnology company ...

Choreo LLC cut its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 23.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange ...

New Mexico Educational Retirement Board decreased its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 2.8% during the fourth quarter, according to the company in its most recent ...

Stock analysts at William Blair increased their Q1 2025 earnings per share (EPS) estimates for shares of Biogen in a research ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize ...

GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.